enGene CEO Pitches Detalimogene as Community-Friendly NMIBC Option, Teases Q2 LEGEND Data Update

Chief Executive Officer Ron Cooper used a presentation at the Citizens Life Sciences Conference to outline the company’s ...

Expanding pediatric urology care in South Texas

Since joining Driscoll in 2024, he has expanded pediatric urology offerings, including new technologies that enable faster ...

Prodeon Medical Receives FDA 510(k) Clearance for the Urocross® Expander System, a Novel Non-Permanent Retrievable Implant for Treating Urinary Symptoms Associated with Benign ...

The Urocross ® Expander System is designed to remodel the obstructed prostatic urethra through a minimally invasive cystoscopy procedure using a non-permanent, intentionally retrievable implant. The ...
UroToday

EAU 2026: Phase 1/2 Study of an Anti-PD-L1/IL-15 Variant Fusion Protein (SIM0237) in BCG Unresponsive High-Risk NMIBC

(UroToday.com) The 2026 European Association of Urology (EAU) annual meeting featured a high-risk non-muscle invasive bladder cancer session and a presentation by Dr. Dingwei Ye discussing results of ...
UroToday

EAU 2026: How to Optimize Tissue Biopsy Acquisition? Why, Who, When, Where, and How

The 2026 European Association of Urology (EAU) annual meeting featured a PARP inhibitors for prostate cancer session and a presentation by Dr. Martin Gleave discussing how to optimize tissue biopsy ...